A5002606926- Hepatocellular Carcinoma Treatment and Prognosis
- Ferroptosis and cancer prognosis
- Cancer, Hypoxia, and Metabolism
- Liver Disease Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Liver Disease and Transplantation
- MicroRNA in disease regulation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Angiogenesis and VEGF in Cancer
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Birth, Development, and Health
- Adipose Tissue and Metabolism
- Advanced Breast Cancer Therapies
- Systemic Sclerosis and Related Diseases
- Lung Cancer Research Studies
- RNA Interference and Gene Delivery
- MRI in cancer diagnosis
- Circular RNAs in diseases
- Adipokines, Inflammation, and Metabolic Diseases
- PARP inhibition in cancer therapy
- Reproductive Biology and Fertility
- Ovarian function and disorders
- Dietary Effects on Health
- Lipid metabolism and disorders
University of Modena and Reggio Emilia
2013-2024
Azienda Ospedaliero-Universitaria di Modena
2021-2023
Gastroenterology Hospital "Saverio de Bellis"
2018
Human luteinizing hormone (hLH) and chorionic gonadotropin (hCG) act on the same receptor (LHCGR) but it is not known whether they elicit cellular molecular response. This study compares for first time activation of cell-signalling pathways gene expression in response to hLH hCG. Using recombinant hCG we evaluated kinetics cAMP production COS-7 hGL5 cells permanently expressing LHCGR (COS-7/LHCGR, hGL5/LHCGR), as well cAMP, ERK1/2, AKT progesterone primary human granulosa (hGLC). The...
The biological heterogeneity of hepatocellular carcinoma (HCC) makes prognosis difficult. We translate the results a genome-wide high-throughput analysis into tool that accurately predicts at presentation tumour growth and survival patients with HCC.Ultrasound surveillance identified HCC in 78 (training set) 54 (validation consecutive cirrhosis. Patients underwent two CT scans 6 weeks apart (no treatment in-between) to determine volumes (V0 V1) calculate doubling time. Baseline-paired...
Recent reports suggested that direct acting antivirals (DAAs) might favor hepatocellular carcinoma (HCC). In study 1, we studied the proangiogenic liver microenvironment in 242 DAA-treated chronic hepatitis C patients with advanced fibrosis. Angiopoietin-2 (ANGPT2) expression was tissue (cirrhotic and/or neoplastic) from recurrent, de novo, nonrecurrent HCC, or never developing HCC. Circulating ANGPT2,vascular endothelial growth factor (VEGF), and C-reactive protein (CRP) were also measured....
Contrasting data exist on the effect of gender and menopause susceptibility, development liver damage progression in non-alcoholic fatty disease (NAFLD). Our aim was to assess whether is associated with severity fibrosis individuals NAFLD explore issue ovarian senescence experimental steatosis zebrafish. In 244 females age-matched males biopsy-proven NAFLD, we assessed anthropometric, biochemical metabolic features, including menopausal status (self-reported); biopsy scored according 'The...
In HCC, tumor microenvironment, heavily influenced by the underlying chronic liver disease, etiology and stage of tissue damage, affects progression determines high heterogeneity tumor. Aim this study was to identify circulating components microenvironment immune-mediated response affecting aggressiveness ensuing clinical outcome. We analyzed baseline paired HCC surrounding biopsies from a prospective cohort 132 patients at first diagnosis for immunolocalization PD-1/PD-L1, FoxP3,...
To the editor, Liver transplantation (LT) is only therapeutic option for both HCC and cirrhosis. Despite careful patient selection, HCC-R_LT occurs in as much 20%, often characterized by an aggressive clinical course high mortality. We therefore designed a proof-of-concept study aimed to analyze safety of combination therapy with nivolumab bevacizumab patients HCC-R_LT, whose tumor progressed most cases while on sorafenib therapy. In particular, we focused risk rejection overall survival...
Aggressive hepatocellular carcinoma (HCC) overexpressing Angiopoietin-2 (ANG-2) (a protein linked with angiogenesis, proliferation, and epithelial–mesenchymal transition (EMT)), shares 95% of up-regulated genes a similar poor prognosis the proliferative subgroup intrahepatic cholangiocarcinoma (iCCA). We analyzed pro-invasive effect ANG-2 its regulator vascular endothelial growth factor (VEGF) on HCC CCA spheroids to uncover posUsible common ways response. Four cell lines were used: Hep3B...
Though the precise criteria for accessing LT are consistently being applied, HCC recurrence (HCC-R_LT) still affects more than 15% of patients. We analyzed clinical, histopathological, and biological features patients with to identify predictive factors associated cancer survival after LT.We retrospectively 441 who underwent in our center. Overall, 70 (15.8%) them developed HCC-R_LT. matched by age at transplant etiology non-recurrent A comparable cohort from Liver Transplant Centre Bologna...
The male/female ratio of patients with hepatocellular carcinoma (HCC) is often unbalanced towards the male sex, indicating a sex predisposition for HCC development. A possible explanation may be attributed to different hormonal statuses, including pro-inflammatory action androgens in men and protective effects oestrogen against excessive inflammation women. Although several studies have studied gene expression HCC, very few attempted identify features that could distinctive between female...
Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide. Curative treatments are available to a minority patients, as HCC often diagnosed at an advanced stage. For patients with unresectable and multifocal HCC, tyrosine kinase inhibitor drugs (TKIs) only potential treatment option. Despite extensive research, predictors response these therapies remain elusive. This study aimed analyze biological histopathological characteristics treated TKIs, focusing on...
: We evaluated the relationship between neoangiogenic transcriptomic signature (nTS) and clinical symptoms, treatment outcomes, survival in hepatocellular carcinoma (HCC) patients.
MicroRNAs (miRNAs) are small, non-coding, single-stranded RNAs of about 22 nucleotides in length. They post-transcriptional modulators gene expression that act predominantly through the degradation their target mRNAs.
Abstract Background & Aims Hepatocellular carcinoma (HCC) is characterized by high clinical and biological heterogeneity, depending on the extremely variable combinations of pathways, linked with immune mechanisms, neo‐angiogenesis, ECM remodeling, metabolism and/or hypoxia. We recently identified a 5‐genes neo‐angiogenic transcriptomic signature (TS), able to discriminate between “aggressive” HCCs (TS‐positive) from “bland” (TS negative), former having poor survival. The aim this study...
Abstract Hepatocellular carcinoma (HCC) has variable prognosis depending both on the severity of underlying liver disease and its biological characteristic. We recently identified, in a prospective series HCCs at first presentation, 5-genes transcriptomic signature, which accurately significantly predicts growth speed survival (Gut. 2015 Feb 9. pii:gutjnl-2014-308483. doi: 10.1136/gutjnl-2014-308483). This signature encounters 5 up-regulated genes (ANGPT2, DLL4, NETO2, ESM1, NR4A1), all...
e16634 Background: Recurrence of hepatocellular carcinoma after liver transplant (LT-HCC), affects ~40% patients. As LT-HCC drastically limits therapeutic options, combination drugs with different mechanism actions might be an attractive approach. Primary objective this MiHRCO (Milciclib and Half Regorafenib CO-administration) protocol (87/2019/COMP/MiHRCO) is to evaluate safety clinical activity (a tyrosine kinase inhibitor higher in aggressive HCC) Milciclib pan cyclin dependent activities...
Abstract Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) are the most common primary liver cancers. Traditionally, both neoplasms considered distinct entities due to their different background. However, comparison of proliferative subgroup iCCA with aggressive HCCs (overexpressing transcriptomic signature (TS) (10.1136/gutjnl-2014-308483)) showed that they share 95% overexpressed genes hold similar severe prognosis. In TS-positive HCCs, expressed gene is...